مدونة صيدلاوى

The FDA has approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema in patients aged 2 years and older.  The FDA has approved Eucrisa (crisaborole) ointment  Eucrisa is applied topically twice daily. Side effects include hypersensitivity reactions, and Eucrisa should not be used in patients who have had a hypersensitivity reaction to crisaborole. The most common side effect is application site pain, including burning or stinging. The safety and efficacy of Eucrisa were established in 2 placebo-controlled trials with a total of 1,522 participants ranging in age from 2 to 79 years of age with mild to moderate atopic dermatitis. Overall, participants receiving Eucrisa achieved greater response with clear or almost clear skin after 28 days of treatment. Atopic dermatitis is the most common of the many types of eczema and typically begins in childhood and lasts through adulthood. The cause of atopic dermatitis is a combination of genetic,...